Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evofem Biosciences, Inc.NEOT · Entity 8607 | Director | June 20, 2017 | June 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evofem Biosciences, Inc.
Report date June 20, 2017 · Filed June 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2027-06-20 | Direct | 12,450 |
Reported balance
After 2017-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-20 · Grant · Acquired 12,450 · Balance 12,450 F1: Option shares fully vest on the earlier of (i) June 20, 2018, (ii) the day preceding the Issuer's annual meeting of stockholders held in 2018, or (iii) immediately prior to a change of control as contemplated by the Issuer's 2014 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Option shares fully vest on the earlier of (i) June 20, 2018, (ii) the day preceding the Issuer's annual meeting of stockholders held in 2018, or (iii) immediately prior to a change of control as contemplated by the Issuer's 2014 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2017 Filed Jun 22, 2017 01:30 UTC | Evofem Biosciences, Inc. NEOT · Entity 8607 | GrantStock Option (Right to Buy) · Derivative | 12,450 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-17-041268 · doc4.xml · derivative · entry 1 Gorbachev Maxim · CIK 0001625238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,450 Underlying: Common Stock · 12,450 shares Expires 2027-06-20 F1 · derivative.exercise_date: Option shares fully vest on the earlier of (i) June 20, 2018, (ii) the day preceding the Issuer's annual meeting of stockholders held in 2018, or (iii) immediately prior to a change of control as contemplated by the Issuer's 2014 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.